BioSpace News Archive

Evofem Biosciences, Inc., announced a series of industry awards and recognition for the company’s direct-to-consumer advertising campaign, House Rules.

Xequel Bio, Inc., a clinical stage biopharmaceutical company developing dermatologic and ophthalmic therapeutics utilizing its patented new chemical entity aCT1, announced the appointments of Michael J. Brubaker, Ph.D., as Chief Scientific Officer and Tony C. Tipton as Chief Operating Officer.

Ecolab Second Quarter Reported Diluted EPS $1.08; Adjusted Diluted EPS $1.10; Expect Improved Second Half 2022 Performance.

Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced the United States Food and Drug Administration (“FDA”) has approved a protocol supplement to the COSIRA-II Investigational Device Exemption (“IDE”) Trial.

International medical imaging IT and cybersecurity company Sectra will install its enterprise imaging system at Cooper University Health Care.

Wilmington, Delaware, United States, Transparency Market Research Inc.: Medication-assisted treatment has become a part of treatment modalities that are combined with counseling and behavioral therapies to provide all-inclusive approach to treating substance use disorders.

Wilmington, Delaware, United States, Transparency Market Research Inc.: Rapid access to pathology test results is critical to high quality and efficient modern healthcare.

Fact.MR – A Market Research and Competitive Intelligence Provider: The global phototherapy devices market reached a valuation of around US$ 750 Mn in 2020, which amounts to around 0.2% share of the overall medical devices market.

According to Transparency Market Research’s latest report on the global pain management devices market for the historical period 2017–2019 and forecast period from 2021 to 2028, increase in the geriatric population, rise in prevalence of chronic diseases, and introduction of novel technologies are projected to boost the growth of the global pain management devices market during the forecast period.

Pixium Vision SA, a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces the successful implantation of the first patient in the Netherlands in the PRIMAvera pivotal trial in atrophic dry age-related macular degeneration.